Male Central Hypogonadism Secondary to Exogenous Androgens

A Review of the Drugs and Protocols Highlighted by the Online Community of Users for Prevention and/or Mitigation of Adverse Effects

Stamatios Karavolos; Michael Reynolds; Nikoletta Panagiotopoulou; Kevin McEleny; Michael Scally; Richard Quinton


Clin Endocrinol. 2015;82(5):624-632. 

In This Article


Widespread misperception that AAS use is safe with manageable adverse effects has contributed to their growing use. When evaluating hypogonadism and infertility, it is important for clinicians to inquire about AAS use because it is more prevalent than is generally thought and AAS users are often reluctant to disclose this to their clinicians.

The long-term adverse consequences of AAS use needs further investigation. Some studies suggest a potential benefit of adjuvant medications in the treatment of ASIH but quality data on the effect and safety of these medications are lacking. The limitations of the present literature with regards to the pathophysiology and treatment of ASIH necessitates more research that will facilitate the reach of consensus on the treatment of ASIH and resultant male infertility.